Evaluation of the evaluation of the putative role of C-C chemokines as protective factors of HIV-1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives

Transfusion

Volumn 40, Issue 4, 2000, Pages 461-467

  Barretina, J ^b   Blanco, J ^b   Gutierrez A ^b   Puig, L ^b   Altisent, C ^b   Espanol, T ^b   Caragol, I ^b   Clotet, B ^b   Esté, José A ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA CHEMOKINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYTOKINE;

ADULT; ARTICLE; BACTERIUM CONTAMINATION; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HEMOPHILIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; BLOOD; EVALUATION; HEMOPHILIA A; PHYSIOLOGY; VIROLOGY;

CHEMOKINES, CC; EVALUATION STUDIES; HEMOPHILIA A; HIV INFECTIONS; HIV-1; HUMANS;

EID: 0034170983     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2000.40040461.x     Document Type: Article

References (43)

1. + T cells. Science 1995;270:1811-5.
2. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is aligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996;382:829-33.
3. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996;382:833-5.
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999;17:657-700.
5. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry co-factor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996;272:872-7.
6. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:;661-6.
7. Buchbinder SP, Katz MH, Hessol NA, et al. Long-term HIV-1 infection without immunologic progression. AIDS 1994;8:1123-8.
8. Easterbrook PJ. Non-progression in HIV infection. AIDS 1994;8:1179-82.
9. Fauci AS. Resistance to HIV-1 infection: it's in the genes. Nat Med 1996;2:966-7.
10. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996;273:1856-62.
11. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply exposed individuals to HIV-1 infection. Cell 1996;86:367-77.
12. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997;3:338-40.
13. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997;3:23-36.
14. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997;277:959-65.
15. Smith MW, Carrington M, Winkler C, et al. CCR2 chemokine receptor and AIDS progression. Nat Med 1997;3:1052-3.
16. Rizzardi GP, Morawetz RA, Vicenzi E, et al. CCR2 polymorphism and HIV disease. Swiss HIV Cohort. Nat Med 1998;4:252-3.
17. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1997;352:866-70.
18. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1α chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort. Science 1998;279:389-93.
19. Mummidi S, Ahuja SS, Gonzalez E, et al. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat Med 1998;4:786-93.
20. Zanussi S, D'Andrea M, Simonelli C, et al. Serum levels of RANTES and MIP-1 alpha in HIV-positive long-term survivors and progresser patients. AIDS 1996;10:1431-2.
21. Weiss L, Si-Mohamed A, Giral P, et al. Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1 alpha and RANTES correlate with virus load in human immunodeficiency virus infection. J Infect Dis 1997;176:1621-4.
22. McKenzie SW, Dallalio G, North M, et al. Serum chemokine levels in patients with non-progressing HIV infection. AIDS 1996;10:F29-33.
23. Zagury D, Lachgar A, Chams V, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci U S A 1998;95:3857-61.
24. Schwartz DH, Castillo RC, Arango-Jaramillo S, et al. Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons. J Infect Dis 1997;176:1168-74.
25. Ullum H, Cozzi A, Victor J, el al. Production of beta-chemokinesin human immunodeficiency virus (HIV) infection: evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression. J Infect Dis 1998;177:331-6.
26. Paxton WA, Liu R, Kang S, et al. Reduced HIV-1 infectability of CD4+lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of beta-chemokines. Virology 1998;244:66-73.
27. Clerici M, Balotta C, Trabattoni D, et al. Chemokine production in HIV-seropositive long-term asymptomatic individuals. AIDS 1996;10:1432-3.
28. Vicenzi E, Bagnarelli P, Santagostino E, et al. Hemophilia and nonprogressing human immunodeficiency virus type 1 infection. Blood 1997;89:191-200.
29. Mackewicz CE, Barker E, Greco G. et al. Do beta-chemokines have clinical relevance in HIV infection? J Clin Invest 1997;100:921-30.
30. Fowke KR, Dong T, Rowland-Jones SL, et al. HIV type 1 resistance in Kenyan sex workers is not associated with altered cellular susceptibility to HIV type 1 infection or enhanced β-chemokine production. AIDS Res Hum Retroviruses 1998;14:1521-30.
31. Blanco J, Cabrera C, Jou A, et al. Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy. AIDS 1999;13:547-55.
32. Sato K, Nagayama H, Takahasi TA. Generation of dendritic cells from fresh and frozen cord blood CD34+ cells. Cryobiology 1998;37:362-71.
33. Sewell WA, North ME, Webster AD, et al. Determination of intracellular cytokines by flow-cytometry following whole blood culture. J Immunol Methods 1997;209:67-74.
34. Madhok R, Gracie JA, Smith J, et al. Capacity to produce interleukin 2 is impaired in haemophilia in the absence and presence of HIV 1 infection. Br J Haematol 1990;76:70-4.
35. Bleul CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A 1997;94:1925-30.
36. Garzino-Demo A, DeVico AL, Cocchi F, et al. β-chemokines and protection from HIV type 1 disease. AIDS Res Hum Retroviruses 1998;14:5177-184.
37. Bubel S, Wilhelm D, Entelmann M, et al. Chemokines in stored platelet concentrates. Transfusion 1996;36:445-9.
38. Kinter A, Catanzaro A, Monaco J, et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4+ T cells: role of signal transduction. Proc Natl Acad Sci U S A 1998;95:11880-5.
39. O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 Δ32 (letter). Lancet 1997;349:1219.
40. Goh WC, Markee J, Akridge E, et al. Protection against human immunodeficiency virus type-1 infection in persons with repeated exposure: evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects. I Infect Dis 1999;179:548-57.
41. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991-8.
42. *04 disadvantage. Science 1999;283:1748-52.
43. Tang J, Costello C, Keet IP, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999;15:317-24.